Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Education

Biotechnology

Appia Bio

JJ Kang

Sylvaine Cases

Monica Jenkins

Alex Babayan

Tessa Aglupos-McCann

David Moskowitz

Jeff Wiezorek

Edmund Kim

Jason Damiano

Scientific Team

Leadership Team

Teams at Appia Bio

Scientific Team

Leadership Team